Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Rejukon Biopharm Inc. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 2 distinct examiners and 2 distinct art units, indicating a focused but divided prosecution landscape. The presence of 2 pending office actions suggests an active engagement with the patent office in this specific technical field.
TIWARI, VYOMA SHUBHAM is identified as the busiest examiner for this portfolio, currently handling 1 pending office action. Since there are 2 distinct examiners in total, the workload is split between different individuals. This distribution across 2 distinct art units suggests that the underlying technologies may span different specialized classifications within the broader Biotechnology & Pharmaceuticals sector.
The use of 2 distinct examiners for the current filings ensures that each matter receives specialized attention. TIWARI, VYOMA SHUBHAM remains a key figure in this process, overseeing 1 pending office action. This structure allows the company to address multiple technical facets of its biopharmaceutical research simultaneously while maintaining a presence in different administrative units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 35.0% | +35.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18836758 | METHODS FOR TREATING CATARACTS USING POLYPEPTIDES | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18836758 | METHODS FOR TREATING CATARACTS USING POLYPEPTIDES | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §102§103§112DP | Non-Final OA | — | Pending | Aug 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRejukon Biopharm Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sara Elizabeth Konopelski Snavel has the most, with 1 of Rejukon Biopharm Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
